Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

303 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and thus reduce the incidence of severe reactions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response

NCT01292356

Metastatic Colon Cancer

COMPLETED PHASE2

Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study

NCT02316496

Colorectal Cancer Metastatic

TERMINATED PHASE2

Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer

NCT01486251

Colorectal Carcinoma

COMPLETED NA

Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer

NCT01243372

Colorectal Cancer

COMPLETED

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

NCT03446157

Cancer of the Colon Colon Cancer Colon Neoplasms +2 more

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cancer Head and Neck Cancer Allergic Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

The IgE anti cetuximab test will then be conducted by an ELISA test

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient informed consent,
* Patient aged over 18 years
* Patients with a WHO performance status ≤ 2,
* Colon cancer or upper aero-digestive tract cytologically or histologically proven
* Patients with an indication to the theoretical use of cetuximab for colon neoplasia or upper aero-digestive tract,
* Haematological and biochemical compatible with combination therapy with cetuximab.